Oncologica is the First UK Genomic Testing Lab to Be Government Approved for Day 2 and Day 8 Testing
- S&P 500, Dow set to ease from record levels; Coca-Cola rises on results
- Bitcoin (BTC) Price Fell 20% Off the Highs Over the Weekend as Markets Got 'Too Excited' About Coinbase (COIN), Says Mike Novogratz
- UK to Intervene on National Security Grounds on NVIDIA (NVDA) and Arm Deal
- GameStop (GME) announces George Sherman will be stepping down as CEO
- Dollar slumps to 6-week low, Bitcoin steadies after weekend drop
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
CAMBRIDGE, England--(BUSINESS WIRE)-- Oncologica, the world-leading cancer medicine and Covid-19 genomic sequencing laboratory is pleased to announce that its Cambridge based testing laboratory is now the first UK laboratory to receive approval by UKAS and the Department of Health and Social Care (DHSC) to perform Covid PCR testing requirements for day 2 and day 8 as part of the new requirements for Covid International travel certification.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005848/en/
The Oncologica Covid-19 PCR testing and genomic sequencing laboratories. (Photo: Business Wire)
The high throughput laboratory which can process up-to 40,000 Covid-19 tests per day, has undergone a rigorous audit process by the DHSC and UKAS inspectors of its Oncology and Covid-19 PCR genomic testing processes for their personalized cancer medicine and Covid-19 PCR testing /viral genomic sequencing services. These testing capabilities will expedite the UK’s return to work and mitigate the risk of superspreading Covid-19 variants in the population. Their state-of-the-art precision cancer medicine genomic profiling services are providing cancer patients with new therapeutic opportunities should standard treatment protocols such as chemotherapy prove inadequate.
Assessments were made of the laboratory’s patient sample collection process, interpretation of results methodologies, turnaround times, as well as an inspection of how the company educates and trains its medical laboratory scientists and clinicians and how the organization communicates and consults with health care professionals.
As of February 15th, 2021, all international travellers to the UK from “red list” countries are required to quarantine for 10 days and undergo a polymerase chain reaction (PCR) Covid-19 test, this is the gold standard for coronavirus detection. On days 2 and 8, if the traveller tests positive, then the sample must be sent to a government-approved lab for genomic sequencing. This is to alert health professionals to potential superspreading coronavirus variants e.g., the UK Kent, Brazilian and South African variants
“It is an honour to be the first UK laboratory Covid PCR test and release provider to achieve accreditation for our Covid-19 International travel testing service. At Oncologica, we are committed to achieving and maintaining the highest standard of quality and service in all aspects of our laboratory testing,” said Dr Marco Loddo, Co-Founder and Scientific Director at Oncologica.
“This commitment is underpinned by the hard work of our entire quality, bioscience and administration teams which has resulted in our achieving this approval.”
“We are immensely proud of Oncologica achieving government approval as the first UK genomic testing laboratory in the UK to be put on the Governments provider list to undertake day 2 and day 8 Covid-19 PCR testing for travel which is no mean feat.” said Professor Gareth Williams, Co-Founder and Medical Director at Oncologica.”
“We are committed to providing a first-class genetic testing service to all of our clinical partners, patients, business community and the general public, and we demonstrate the highest quality standards whether it is for improving cancer treatment opportunities for patients or for Covid-19 testing across the community. Covid-19 testing is presently being undertaken for businesses, offices, factories, educational institutions, and transport networks facilitating a safe return to work and enabling people to travel."
“On receipt of our Coronafocus© self-sampling PCR kits, we extract the RNA genetic material out of the sample and copy it into DNA. Now if the virus is there, it is in a DNA form. We put it into a PCR reaction (Polymerase Chain Reaction) and take short snippets of DNA and match these to the virus DNA. If we find the virus DNA, we start a chemical reaction that copies the virus again and again, so that we have lots of copies. We then look at the sample copies. If there is no reaction, then no virus is detected. The Oncologica Covid-19 PCR test is very specific, and accurate. It can detect as little as one virus particle. If the Oncologica test finds it, you can believe it.”
“We understand the importance of our medical genomic laboratory to patient care. Therefore, for those who use our Oncofocus© cancer and Coronafocus© Covid PCR tests, this accreditation will give added assurance that their testing requirements will be performed to the highest standards for rapid and accurate results,” added Marco Loddo. Read more at https://covid19.oncologica.com/coronafocus-day2-day8/
Oncologica is a world leading precision cancer medicine and Covid-19 testing and genomic sequencing laboratory based in Cambridge, UK. Our personalised cancer DNA profiling is used to precisely identify the most appropriate clinical targeted therapies and/or immunotherapies which can be used to treat patients as an alternative to chemotherapy.
Our molecular Next Generation Sequencing capabilities are used to sequence tumour DNA and to also sequence Covid-19/ SARS-CoV-2 for virus mutations. SARS-CoV-2 testing, and sequencing is being used to identify high risk Covid-19 variants which can potentially bypass the vaccine. Oncologica’s comprehensive NGS DNA profiling covering 505 genes with linkage to over 750 targeted therapies provide patients and clinicians with detailed genomic blueprints that optimize therapy choices, improve outcomes, and helps avoid treatment with drugs unlikely to be of benefit.
Oncologica also undertakes Contract Research supporting biomarker development programmes, clinical trials, and the validation of new diagnostic testing platforms. Our in-house R&D activities focus on the development of novel cancer genomic based diagnostic and therapeutic approaches directed at specific tumour gene mutations or aberrant cancer pathways.
Our government approved Oncofocus© and Coronofocus© laboratory tests are used by state healthcare providers and the private sector including businesses, factories, healthcare providers, transport, and educational institutions. Personalised genomic data is helping to empower patients and clinicians to increase treatment efficacy and improve human health.
Oncologica UK Ltd, Suite 2, The Newnham Building, Chesterford Research Park, CAMBRIDGE UK CB10 1XL
Dr Marco Leddo BSc PhD, Co-Founder and Scientific Director
Tel Dir: 01223 785316
Editorial and press enquiries
Christine Modla-Thomas, Marketing Manager
Tel Dir: 01223 981779
firstname.lastname@example.org or Tel: 01223 785327
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Diabetes Reversal Leader Virta Health Raises $133M Series E to Take Type 2 Diabetes Reversal Mainstream
- Kurita Expands Presence in North America, Completes Acquisition of Keytech Water Management of Canada
- Alpha Auto Group Q4 2020 Earnings Call Invitation
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!